Tepnel raises fresh funds and scales up research and development:
This article was originally published in Clinica
Tepnel Life Sciences, the UK developer of DNA diagnostics, has raised £9.1 million ($14.6 million) net in a rights issue. The company reported after reporting turnover of £134,000 mainly from sales of its Faras antibiotic testing kits in the six months to December 1996. The company's net loss rose 30% to £650,000 after the scale-up of R&D. Some 15 Daras instruments are scheduled for delivery in April for testing.
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.